Novel insights into the pathogenic impact of diabetes on the gastrointestinal tract.
autonomic neuropathy
constipation
diarrhoea
digestion
gallstone disease
gastroesophageal reflux
gastrointestinal hormones
gastrointestinal motility
gastroparesis
insulin resistance
obesity
Journal
European journal of clinical investigation
ISSN: 1365-2362
Titre abrégé: Eur J Clin Invest
Pays: England
ID NLM: 0245331
Informations de publication
Date de publication:
Nov 2022
Nov 2022
Historique:
revised:
20
06
2022
received:
28
05
2022
accepted:
26
06
2022
pubmed:
30
7
2022
medline:
15
10
2022
entrez:
29
7
2022
Statut:
ppublish
Résumé
Type 2 and type 1 diabetes are common endocrine disorders with a progressively increasing incidence worldwide. These chronic, systemic diseases have multiorgan implications, and the whole gastrointestinal (GI) tract represents a frequent target in terms of symptom appearance and interdependent pathophysiological mechanisms. Metabolic alterations linked with diabetic complications, neuropathy and disrupted hormone homeostasis can lead to upper and/or lower GI symptoms in up to 75% of diabetic patients, with multifactorial involvement of the oesophagus, stomach, upper and lower intestine, and of the gallbladder. On the other hand, altered gastrointestinal motility and/or secretions are able to affect glucose and lipid homeostasis in the short and long term. Finally, diabetes has been linked with increased cancer risk at different levels of the GI tract. The presence of GI symptoms and a comprehensive assessment of GI function should be carefully considered in the management of diabetic patients to avoid further complications and to ameliorate the quality of life. Additionally, the presence of gastrointestinal dysfunction should be adequately managed to improve metabolic homeostasis, the efficacy of antidiabetic treatments and secondary prevention strategies.
Substances chimiques
Hormones
0
Hypoglycemic Agents
0
Lipids
0
Glucose
IY9XDZ35W2
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13846Informations de copyright
© 2022 Stichting European Society for Clinical Investigation Journal Foundation. Published by John Wiley & Sons Ltd.
Références
Ueberberg S, Nauck MA, Uhl W, et al. Islet amyloid in patients with diabetes due to exocrine pancreatic disorders, type 2 diabetes, and nondiabetic patients. J Clin Endocrinol Metab. 2020;105:2595-2605.
Davis SN, Piatti PM, Monti L, et al. Proinsulin and insulin concentrations following intravenous glucose challenges in normal, obese, and non-insulin-dependent diabetic subjects. Metabolism. 1993;42:30-35.
Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes. 2003;52:102-110.
Sakuraba H, Mizukami H, Yagihashi N, Wada R, Hanyu C, Yagihashi S. Reduced beta-cell mass and expression of oxidative stress-related DNA damage in the islet of Japanese Type II diabetic patients. Diabetologia. 2002;45:85-96.
Rahier J, Guiot Y, Goebbels RM, Sempoux C, Henquin JC. Pancreatic beta-cell mass in European subjects with type 2 diabetes. Diabetes Obes Metab. 2008;10(Suppl 4):32-42.
Aguayo-Mazzucato C, Midha A. beta-cell senescence in type 2 diabetes. Aging (Albany NY). 2019;11:9967-9968.
Bruni A, Bornstein S, Linkermann A, Shapiro AJ. Regulated cell death seen through the lens of islet transplantation. Cell Transplant. 2018;27:890-901.
Bensellam M, Jonas JC, Laybutt DR. Mechanisms of beta-cell dedifferentiation in diabetes: recent findings and future research directions. J Endocrinol. 2018;236:R109-R143.
Costes S, Bertrand G, Ravier MA. Mechanisms of beta-cell apoptosis in type 2 diabetes-prone situations and potential protection by GLP-1-based therapies. Int J Mol Sci. 2021;22:5303.
Masini M, Martino L, Marselli L, et al. Ultrastructural alterations of pancreatic beta cells in human diabetes mellitus. Diabetes Metab Res Rev. 2017;33:e2894.
Marchetti P, Del Guerra S, Marselli L, et al. Pancreatic islets from type 2 diabetic patients have functional defects and increased apoptosis that are ameliorated by metformin. J Clin Endocrinol Metab. 2004;89:5535-5541.
American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2007;30:S42-S47.
Holt RIG, DeVries JH, Hess-Fischl A, et al. The management of type 1 diabetes in adults. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2021;44:2589-2625.
Mobasseri M, Shirmohammadi M, Amiri T, Vahed N, Fard HH, Ghojazadeh M. Prevalence and incidence of type 1 diabetes in the world: a systematic review and meta-analysis. Health Promot Perspect. 2020;10:98.
Pearson JA, Agriantonis A, Wong FS, Wen L. Modulation of the immune system by the gut microbiota in the development of type 1 diabetes. Hum Vaccines Immunother. 2018;14:2580-2596.
Aydin Ö, Nieuwdorp M, Gerdes V. The gut microbiome as a target for the treatment of type 2 diabetes. Curr Diab Rep. 2018;18:55.
Di Ciaula A, Garruti G, Lunardi Baccetto R, et al. Bile acid physiology. Ann Hepatol. 2017;16:s4-s14.
Wu H, Esteve E, Tremaroli V, et al. Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug. Nat Med. 2017;23:850-858.
American Diabetes Association. 4. Comprehensive medical evaluation and assessment of comorbidities: standards of medical care in diabetes-2020. Diabetes Care. 2020;43:S37-S47.
Dieleman JL, Baral R, Birger M, et al. US spending on personal health care and public health, 1996-2013. JAMA. 2016;316:2627-2646.
Kan C, Silva N, Golden SH, et al. A systematic review and meta-analysis of the association between depression and insulin resistance. Diabetes Care. 2013;36:480-489.
Tunceli K, Bradley CJ, Nerenz D, Williams LK, Pladevall M, Elston LJ. The impact of diabetes on employment and work productivity. Diabetes Care. 2005;28:2662-2667.
American Diabetes Association. Economic costs of diabetes in the U.S. in 2017. Diabetes Care. 2018;41:917-928.
American Diabetes Association. 11. Microvascular complications and foot care: standards of medical care in diabetes-2020. Diabetes Care. 2020;43:S135-S151.
Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41:255-323.
American Diabetes Association. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2019. Diabetes Care. 2019;42:S13-S28.
Wang HH, Lee DK, Liu M, Portincasa P, Wang DQ. Novel insights into the pathogenesis and management of the metabolic syndrome. Pediatr Gastroenterol Hepatol Nutr. 2020;23:189-230.
Younossi ZM, Paik JM, Al Shabeeb R, Golabi P, Younossi I, Henry L. Are there outcomes differences between non-alcoholic fatty liver disease (NAFLD) and metabolic associated fatty liver disease (MAFLD)? Hepatology. 2022:1-15
Callaghan BC, Gallagher G, Fridman V, Feldman EL. Diabetic neuropathy: what does the future hold? Diabetologia. 2020;63:891-897.
Eid S, Sas KM, Abcouwer SF, et al. New insights into the mechanisms of diabetic complications: role of lipids and lipid metabolism. Diabetologia. 2019;62:1539-1549.
Garruti G, Giampetruzzi F, Vita M, et al. Links between metabolic syndrome and cardiovascular autonomic dysfunction. Exp Diabetes Res. 2012;2012:1-9.
Vinik AI, Maser RE, Mitchell BD, Freeman R. Diabetic autonomic neuropathy. Diabetes Care. 2003;26:1553-1579.
Toyry JP, Niskanen LK, Mantysaari MJ, Lansimies EA, Uusitupa MI. Occurrence, predictors, and clinical significance of autonomic neuropathy in NIDDM. Ten-year follow-up from the diagnosis. Diabetes. 1996;45:308-315.
Uusitupa M, Niskanen L, Laitinen T. Divergent pathologies and treatment options for diabetic neuropathies. Diabetologia. 2020;63:1947-1948.
Di Ciaula A, Wang DQH, Sommers T, Lembo A, Portincasa P. Impact of endocrine disorders on gastrointestinal diseases. In: Portincasa P, Frühbeck G, eds. Endocrinology and Systemic Diseases. Springer International Publishing; 2019:1-47.
Idrizaj E, Traini C, Vannucchi MG, Baccari MC. Nitric oxide: from gastric motility to gastric dysmotility. Int J Mol Sci. 2021;22:9990.
Izbéki F, Wittman T, Rosztóczy A, et al. Immediate insulin treatment prevents gut motility alterations and loss of nitrergic neurons in the ileum and colon of rats with streptozotocin-induced diabetes. Diabetes Res Clin Pract. 2008;80:192-198.
Matsumoto M, Yoshimura R, Akiho H, et al. Gastric emptying in diabetic patients by the 13C-octanoic acid breath test: role of insulin in gastric motility. J Gastroenterol. 2007;42:469-474.
Russo A, Stevens JE, Chen R, et al. Insulin-induced hypoglycemia accelerates gastric emptying of solids and liquids in long-standing type 1 diabetes. J Clin Endocrinol Metab. 2005;90:4489-4495.
Fraser RJ, Horowitz M, Maddox AF, Harding PE, Chatterton BE, Dent J. Hyperglycaemia slows gastric emptying in type 1 (insulin-dependent) diabetes mellitus. Diabetologia. 1990;33:675-680.
Moran O, Phillip M. Leptin: obesity, diabetes and other peripheral effects-a review. Pediatr Diabetes. 2003;4:101-109.
Ruige JB, Dekker JM, Blum WF, et al. Leptin and variables of body adiposity, energy balance, and insulin resistance in a population-based study. The Hoorn study. Diabetes Care. 1999;22:1097-1104.
Buyse M, Ovesjo ML, Goiot H, et al. Expression and regulation of leptin receptor proteins in afferent and efferent neurons of the vagus nerve. Eur J Neurosci. 2001;14:64-72.
Asakawa A, Inui A, Ueno N, Makino S, Fujino MA, Kasuga M. Urocortin reduces food intake and gastric emptying in lean and ob/ob obese mice. Gastroenterology. 1999;116:1287-1292.
Martinez V, Barrachina MD, Wang L, Tache Y. Intracerebroventricular leptin inhibits gastric emptying of a solid nutrient meal in rats. Neuroreport. 1999;10:3217-3221.
Hata N, Murata S, Maeda J, et al. Predictors of gastric myoelectrical activity in type 2 diabetes mellitus. J Clin Gastroenterol. 2009;43:429-436.
Kiely JM, Noh JH, Graewin SJ, Pitt HA, Swartz-Basile DA. Altered intestinal motility in leptin-deficient obese mice1. J Surg Res. 2005;124:98-103.
Guilmeau S, Buyse M, Tsocas A, Laigneau JP, Bado A. Duodenal leptin stimulates cholecystokinin secretion: evidence of a positive leptin-cholecystokinin feedback loop. Diabetes. 2003;52:1664-1672.
Gaige S, Abysique A, Bouvier M. Effects of leptin on cat intestinal motility. J Physiol. 2003;546:267-277.
Xita N, Tsatsoulis A. Adiponectin in diabetes mellitus. Curr Med Chem. 2012;19:5451-5458.
Kato M, Watabe K, Hamasaki T, et al. Association of low serum adiponectin levels with erosive esophagitis in men: an analysis of 2405 subjects undergoing physical check-ups. J Gastroenterol. 2011;46:1361-1367.
Krishnan B, Babu S, Walker J, Walker AB, Pappachan JM. Gastrointestinal complications of diabetes mellitus. World J Diabetes. 2013;4:51-63.
Nauck MA, Vardarli I, Deacon CF, Holst JJ, Meier JJ. Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down? Diabetologia. 2011;54:10-18.
Poher AL, Tschop MH, Muller TD. Ghrelin regulation of glucose metabolism. Peptides. 2018;100:236-242.
Asakawa A, Inui A, Kaga T, et al. Ghrelin is an appetite-stimulatory signal from stomach with structural resemblance to motilin. Gastroenterology. 2001;120:337-345.
Masuda Y, Tanaka T, Inomata N, et al. Ghrelin stimulates gastric acid secretion and motility in rats. Biochem Biophys Res Commun. 2000;276:905-908.
Pöykkö SM, Kellokoski E, Hörkkö S, Kauma H, Kesäniemi YA, Ukkola O. Low plasma ghrelin is associated with insulin resistance, hypertension, and the prevalence of type 2 diabetes. Diabetes. 2003;52:2546-2553.
Han W, Cui C, Zhang H, et al. Ghrelin ameliorates diabetes-associated behavioral deficits and NLRP3 inflammasome activation via autophagic flux enhancement. Pharmacol Res. 2022;179:106224.
Gangula PR, Maner WL, Micci M-A, Garfield RE, Pasricha PJ. Diabetes induces sex-dependent changes in neuronal nitric oxide synthase dimerization and function in the rat gastric antrum. Am J Physiol Gastrointest Liver Physiol. 2007;292:G725-G733.
Monreal-Robles R, Remes-Troche JM. Diabetes and the esophagus. Curr Treat Options Gastroenterol. 2017;15:475-489.
Marathe CS, Jones KL, Wu T, Rayner CK, Horowitz M. Gastrointestinal autonomic neuropathy in diabetes. Auton Neurosci. 2020;229:102718.
Ricci JA, Siddique R, Stewart WF, Sandler RS, Sloan S, Farup CE. Upper gastrointestinal symptoms in a U.S. national sample of adults with diabetes. Scand J Gastroenterol. 2000;35:152-159.
Ko GT, Chan WB, Chan JC, Tsang LW, Cockram CS. Gastrointestinal symptoms in Chinese patients with Type 2 diabetes mellitus. Diabet Med. 1999;16:670-674.
Clouse RE, Lustman PJ. Gastrointestinal symptoms in diabetic patients: lack of association with neuropathy. Am J Gastroenterol. 1989;84:868-872.
Quan C, Talley NJ, Cross S, et al. Development and validation of the Diabetes Bowel Symptom Questionnaire. Aliment Pharmacol Ther. 2003;17:1179-1187.
Camilleri M. Clinical practice. Diabetic gastroparesis. N Engl J Med. 2007;356:820-829.
Zhao J, Gregersen H. Diabetes-induced mechanophysiological changes in the esophagus. Ann N Y Acad Sci. 2016;1380:139-154.
Lin J, Liu G, Duan Z. The mechanism of esophagus dysmotility in diabetes and research progress of relating treatments. Expert Rev Gastroenterol Hepatol. 2021;15:919-927.
Lluch I, Ascaso JF, Mora F, et al. Gastroesophageal reflux in diabetes mellitus. Am J Gastroenterol. 1999;94:919-924.
Lee SD, Keum B, Chun HJ, Bak YT. Gastroesophageal reflux disease in type II diabetes mellitus with or without peripheral neuropathy. J Neurogastroenterol Motil. 2011;17:274-278.
Iyer PG, Borah BJ, Heien HC, Das A, Cooper GS, Chak A. Association of Barrett's esophagus with type II diabetes mellitus: results from a large population-based case-control study. Clin Gastroenterol Hepatol. 2013;11:1108-1114. e5.
Roman S, Marjoux S, Thivolet C, Mion F. Oesophageal function assessed by high-resolution manometry in patients with diabetes and inadequate glycaemic control. Diabet Med. 2014;31:1452-1459.
Xu B, Zhou X, Li X, Liu C, Yang C. Diabetes mellitus carries a risk of esophageal cancer: a meta-analysis. Medicine (Baltimore). 2017;96:e7944.
Elliott JA, Reynolds JV. Visceral obesity, metabolic syndrome, and esophageal adenocarcinoma. Front Oncol. 2021;11:627270.
Chang ML, Yang Z, Yang SS. Roles of adipokines in digestive diseases: markers of inflammation, metabolic alteration and disease progression. Int J Mol Sci. 2020;21:8308.
Koch KL, Calles-Escandon J. Diabetic gastroparesis. Gastroenterol Clin North Am. 2015;44:39-57.
Neshatian L, Gibbons SJ, Farrugia G. Macrophages in diabetic gastroparesis-the missing link? Neurogastroenterol Motil. 2015;27:7-18.
Yarandi SS, Srinivasan S. Diabetic gastrointestinal motility disorders and the role of enteric nervous system: current status and future directions. Neurogastroenterol Motil. 2014;26:611-624.
Parkman HP, Hasler WL, Fisher RS, American Gastroenterological Association. American Gastroenterological Association technical review on the diagnosis and treatment of gastroparesis. Gastroenterology. 2004;127:1592-1622.
Parkman HP, Hasler WL, Fisher RS, American Gastroenterological Association. American Gastroenterological Association medical position statement: diagnosis and treatment of gastroparesis. Gastroenterology. 2004;127:1589-1591.
Bharucha AE, Daley SL, Low PA, et al. Effects of hemin on heme oxygenase-1, gastric emptying, and symptoms in diabetic gastroparesis. Neurogastroenterol Motil. 2016;28:1731-1740.
Mearin F, Malagelada JR. Gastroparesis and dyspepsia in patients with diabetes mellitus. Eur J Gastroenterol Hepatol. 1995;7:717-723.
Horowitz M, Edelbroek M, Fraser R, Maddox A, Wishart J. Disordered gastric motor function in diabetes mellitus. Recent insights into prevalence, pathophysiology, clinical relevance, and treatment. Scand J Gastroenterol. 1991;26:673-684.
Wegener M, Borsch G, Schaffstein J, Luerweg C, Leverkus F. Gastrointestinal transit disorders in patients with insulin-treated diabetes mellitus. Dig Dis. 1990;8:23-36.
Buysschaert M, Moulart M, Urbain JL, et al. Impaired gastric emptying in diabetic patients with cardiac autonomic neuropathy. Diabetes Care. 1987;10:448-452.
Ducrotte P, Coffin B, Bonaz B, et al. Gastric electrical stimulation reduces refractory vomiting in a randomized crossover trial. Gastroenterology. 2020;158:506-514. e2.
Hasler WL, May KP, Wilson LA, et al. Relating gastric scintigraphy and symptoms to motility capsule transit and pressure findings in suspected gastroparesis. Neurogastroenterol Motil. 2018;30:e13196. doi:10.1111/nmo.13196
Janssen P, Harris MS, Jones M, et al. The relation between symptom improvement and gastric emptying in the treatment of diabetic and idiopathic gastroparesis. Am J Gastroenterol. 2013;108:1382-1391.
Hasler WL. Gastroparesis: pathogenesis, diagnosis and management. Nat Rev Gastroenterol Hepatol. 2011;8:438-453.
Pasricha PJ, Colvin R, Yates K, et al. Characteristics of patients with chronic unexplained nausea and vomiting and normal gastric emptying. Clin Gastroenterol Hepatol. 2011;9:567-576. e1-4.
Bharucha AE, Camilleri M, Forstrom LA, Zinsmeister AR. Relationship between clinical features and gastric emptying disturbances in diabetes mellitus. Clin Endocrinol (Oxf). 2009;70:415-420.
Jones KL, Russo A, Stevens JE, Wishart JM, Berry MK, Horowitz M. Predictors of delayed gastric emptying in diabetes. Diabetes Care. 2001;24:1264-1269.
Galil MA, Critchley M, Mackie CR. Isotope gastric emptying tests in clinical practice: expectation, outcome, and utility. Gut. 1993;34:916-919.
Horowitz M, Maddox AF, Wishart JM, Harding PE, Chatterton BE, Shearman DJ. Relationships between oesophageal transit and solid and liquid gastric emptying in diabetes mellitus. Eur J Nucl Med. 1991;18:229-234.
Lembo A, Camilleri M, McCallum R, et al. Relamorelin reduces vomiting frequency and severity and accelerates gastric emptying in adults with diabetic gastroparesis. Gastroenterology. 2016;151:87, e6-96.
Horowitz M, Wishart JM, Jones KL, Hebbard GS. Gastric emptying in diabetes: an overview. Diabet Med. 1996;13:S16-S22.
Rathmann W, Enck P, Frieling T, Gries FA. Visceral afferent neuropathy in diabetic gastroparesis. Diabetes Care. 1991;14:1086-1089.
Bytzer P, Talley NJ, Hammer J, Young LJ, Jones MP, Horowitz M. GI symptoms in diabetes mellitus are associated with both poor glycemic control and diabetic complications. Am J Gastroenterol. 2002;97:604-611.
Barnett JL, Owyang C. Serum glucose concentration as a modulator of interdigestive gastric motility. Gastroenterology. 1988;94:739-744.
Schvarcz E, Palmer M, Aman J, Horowitz M, Stridsberg M, Berne C. Physiological hyperglycemia slows gastric emptying in normal subjects and patients with insulin-dependent diabetes mellitus. Gastroenterology. 1997;113:60-66.
Rayner CK, Horowitz M. Gastrointestinal motility and glycemic control in diabetes: the chicken and the egg revisited? J Clin Invest. 2006;116:299-302.
Jalleh R, Marathe CS, Rayner CK, Jones KL, Horowitz M. Diabetic gastroparesis and glycaemic control. Curr Diab Rep. 2019;19:153.
Mihai BM, Mihai C, Cijevschi-Prelipcean C, et al. Bidirectional relationship between gastric emptying and plasma glucose control in normoglycemic individuals and diabetic patients. J Diabetes Res. 2018;2018:1736959.
Jebbink HJ, Bruijs PP, Bravenboer B, Akkermans LM, van Berge-Henegouwen GP, Smout AJ. Gastric myoelectrical activity in patients with type I diabetes mellitus and autonomic neuropathy. Dig Dis Sci. 1994;39:2376-2383.
Jebbink RJ, Samsom M, Bruijs PP, et al. Hyperglycemia induces abnormalities of gastric myoelectrical activity in patients with type I diabetes mellitus. Gastroenterology. 1994;107:1390-1397.
Kumar A, Attaluri A, Hashmi S, Schulze KS, Rao SS. Visceral hypersensitivity and impaired accommodation in refractory diabetic gastroparesis. Neurogastroenterol Motil. 2008;20:635-642.
Fraser R, Horowitz M, Dent J. Hyperglycaemia stimulates pyloric motility in normal subjects. Gut. 1991;32:475-478.
Horowitz M, Harding PE, Maddox AF, et al. Gastric and oesophageal emptying in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia. 1989;32:151-159.
Rayner CK, Samsom M, Jones KL, Horowitz M. Relationships of upper gastrointestinal motor and sensory function with glycemic control. Diabetes Care. 2001;24:371-381.
Chang J, Russo A, Bound M, Rayner CK, Jones KL, Horowitz M. A 25-year longitudinal evaluation of gastric emptying in diabetes. Diabetes Care. 2012;35:2594-2596.
Bharucha AE, Batey-Schaefer B, Cleary PA, et al. Delayed gastric emptying is associated with early and long-term hyperglycemia in type 1 diabetes mellitus. Gastroenterology. 2015;149:330-339.
Izzy M, Lee M, Johns-Keating K, et al. Glycosylated hemoglobin level may predict the severity of gastroparesis in diabetic patients. Diabetes Res Clin Pract. 2018;135:45-49.
Reddy S, Ramsubeik K, Vega KJ, Federico J, Palacio C. Do HbA1C levels correlate with delayed gastric emptying in diabetic patients? J Neurogastroenterol Motil. 2010;16:414-417.
Merio R, Festa A, Bergmann H, et al. Slow gastric emptying in type I diabetes: relation to autonomic and peripheral neuropathy, blood glucose, and glycemic control. Diabetes Care. 1997;20:419-423.
Schvarcz E, Palmer M, Aman J, Lindkvist B, Beckman KW. Hypoglycaemia increases the gastric emptying rate in patients with type 1 diabetes mellitus. Diabet Med. 1993;10:660-663.
Groop LC, Luzi L, DeFronzo RA, Melander A. Hyperglycaemia and absorption of sulphonylurea drugs. Lancet. 1989;2:129-130.
Parkman HP, Yates K, Hasler WL, et al. Similarities and differences between diabetic and idiopathic gastroparesis. Clin Gastroenterol Hepatol. 2011;9:1056-1064. quiz e133-4.
Parkman HP, Fass R, Foxx-Orenstein AE. Treatment of patients with diabetic gastroparesis. Gastroenterol Hepatol (N Y). 2010;6:1-16.
Parthasarathy G, Kudva YC, Low PA, Camilleri M, Basu A, Bharucha AE. Relationship between gastric emptying and diurnal glycemic control in type 1 diabetes mellitus: a randomized trial. J Clin Endocrinol Metab. 2017;102:398-406.
Perano SJ, Rayner CK, Kritas S, et al. Gastric emptying is more rapid in adolescents with type 1 diabetes and impacts on postprandial glycemia. J Clin Endocrinol Metab. 2015;100:2248-2253.
Lysy J, Israeli E, Strauss-Liviatan N, Goldin E. Relationships between hypoglycaemia and gastric emptying abnormalities in insulin-treated diabetic patients. Neurogastroenterol Motil. 2006;18:433-440.
Lupoli R, Pisano F, Capaldo B. Postprandial glucose control in type 1 diabetes: importance of the gastric emptying rate. Nutrients. 2019;11:1559.
Frokjaer JB, Andersen SD, Ejskjaer N, Funch-Jensen P, Drewes AM, Gregersen H. Impaired contractility and remodeling of the upper gastrointestinal tract in diabetes mellitus type-1. World J Gastroenterol. 2007;13:4881-4890.
Chedid V, Brandler J, Vijayvargiya P, Park SY, Szarka LA, Camilleri M. Characterization of upper gastrointestinal symptoms, gastric motor functions, and associations in patients with diabetes at a referral center. Am J Gastroenterol. 2019;114:143-154.
Aleppo G, Calhoun P, Foster NC, et al. Reported gastroparesis in adults with type 1 diabetes (T1D) from the T1D Exchange clinic registry. J Diabetes Complications. 2017;31:1669-1673.
Kong MF, Horowitz M, Jones KL, Wishart JM, Harding PE. Natural history of diabetic gastroparesis. Diabetes Care. 1999;22:503-507.
Watson LE, Phillips LK, Wu T, et al. Longitudinal evaluation of gastric emptying in type 2 diabetes. Diabetes Res Clin Pract. 2019;154:27-34.
Portincasa P, Di Ciaula A, Palmieri V, Van Berge-Henegouwen GP, Palasciano G. Effects of cholestyramine on gallbladder and gastric emptying in obese and lean subjects. Eur J Clin Invest. 1995;25:746-753.
Luiking YC, Peeters TL, Stolk MF, et al. Motilin induces gall bladder emptying and antral contractions in the fasted state in humans. Gut. 1998;42:830-835.
Portincasa P, Colecchia A, Di Ciaula A, et al. Standards for diagnosis of gastrointestinal motility disorders. Section: ultrasonography. A position statement from the Gruppo Italiano di Studio Motilita Apparato Digerente. Dig Liver Dis. 2000;32:160-172.
Rizzello CG, Portincasa P, Montemurro M, et al. Sourdough fermented breads are more digestible than those started with baker's yeast alone: an in vivo challenge dissecting distinct gastrointestinal responses. Nutrients. 2019;11:2954.
Perri F, Bellini M, Portincasa P, et al. (13)C-octanoic acid breath test (OBT) with a new test meal (EXPIROGer): toward standardization for testing gastric emptying of solids. Dig Liver Dis. 2010;42:549-553.
Bonfrate L, Grattagliano I, Palasciano G, Portincasa P. Dynamic carbon 13 breath tests for the study of liver function and gastric emptying. Gastroenterol Rep (Oxf). 2015;3:12-21.
Schwizer W, Maecke H, Fried M. Measurement of gastric emptying by magnetic resonance imaging in humans. Gastroenterology. 1992;103:369-376.
Jones KL, Russo A, Berry MK, Stevens JE, Wishart JM, Horowitz M. A longitudinal study of gastric emptying and upper gastrointestinal symptoms in patients with diabetes mellitus. Am J Med. 2002;113:449-455.
Kurniawan AH, Suwandi BH, Kholili U. Diabetic gastroenteropathy: a complication of diabetes mellitus. Acta Med Indones. 2019;51:263-271.
Woerle HJ, Albrecht M, Linke R, et al. Impaired hyperglycemia-induced delay in gastric emptying in patients with type 1 diabetes deficient for islet amyloid polypeptide. Diabetes Care. 2008;31:2325-2331.
Fineman MS, Koda JE, Shen LZ, et al. The human amylin analog, pramlintide, corrects postprandial hyperglucagonemia in patients with type 1 diabetes. Metabolism. 2002;51:636-641.
Kong MF, Stubbs TA, King P, et al. The effect of single doses of pramlintide on gastric emptying of two meals in men with IDDM. Diabetologia. 1998;41:577-583.
Jung HK, Kim DY, Moon IH, Hong YS. Colonic transit time in diabetic patients-comparison with healthy subjects and the effect of autonomic neuropathy. Yonsei Med J. 2003;44:265-272.
Iida M, Ikeda M, Kishimoto M, et al. Evaluation of gut motility in type II diabetes by the radiopaque marker method. J Gastroenterol Hepatol. 2000;15:381-385.
Kawagishi T, Nishizawa Y, Okuno Y, Sekiya K, Morii H. Segmental gut transit in diabetes mellitus: effect of cisapride. Diabetes Res Clin Pract. 1992;17:137-144.
Taba Taba Vakili S, Nezami BG, Shetty A, Chetty VK, Srinivasan S. Association of high dietary saturated fat intake and uncontrolled diabetes with constipation: evidence from the National Health and Nutrition Examination Survey. Neurogastroenterol Motil. 2015;27:1389-1397.
von der Ohe MR. Diarrhoea in patients with diabetes mellitus. Eur J Gastroenterol Hepatol. 1995;7:730-736.
Duchen LW, Anjorin A, Watkins PJ, Mackay JD. Pathology of autonomic neuropathy in diabetes mellitus. Ann Intern Med. 1980;92:301-303.
Low PA, Walsh JC, Huang CY, McLeod JG. The sympathetic nervous system in alcoholic neuropathy. A clinical and pathological study. Brain. 1975;98:357-364.
Gotfried J, Priest S, Schey R. Diabetes and the small intestine. Curr Treat Options Gastroenterol. 2017;15:490-507.
He C-L, Szurszewski JH, Farrugia G, et al. Loss of interstitial cells of cajal and inhibitory innervation in insulin-dependent diabetes. Gastroenterology. 2001;121:427-434.
Dandona P, Fonseca V, Mier A, Beckett AG. Diarrhea and metformin in a diabetic clinic. Diabetes Care. 1983;6:472-474.
Gasbarrini A, Corazza GR, Gasbarrini G, et al. Methodology and indications of H2-breath testing in gastrointestinal diseases: the Rome Consensus Conference. Aliment Pharmacol Ther. 2009;29(Suppl 1):1-49.
Wald A. Incontinence and anorectal dysfunction in patients with diabetes mellitus. Eur J Gastroenterol Hepatol. 1995;7:737-739.
Lysy J, Israeli E, Goldin E. The prevalence of chronic diarrhea among diabetic patients. Am J Gastroenterol. 1999;94:2165-2170.
Badiga MS, Jain NK, Casanova C, Pitchumoni CS. Diarrhea in diabetics: the role of sorbitol. J Am Coll Nutr. 1990;9:578-582.
Bytzer P, Talley NJ, Jones MP, Horowitz M. Oral hypoglycaemic drugs and gastrointestinal symptoms in diabetes mellitus. Aliment Pharmacol Ther. 2001;15:137-142.
el Newihi H, Dooley CP, Saad C, Staples J, Zeidler A, Valenzuela JE. Impaired exocrine pancreatic function in diabetics with diarrhea and peripheral neuropathy. Dig Dis Sci. 1988;33:705-710.
Shanahan F, McKenna R, McCarthy C, Drury M. Coeliac disease and diabetes millitus: a study of 24 patients with HLA typing. QJM: Int J Med. 1982;51:329-335.
Cudworth AG, Woodrow JC. Genetic susceptibility in diabetes mellitus: analysis of the HLA association. Br Med J. 1976;2:846-848.
Portincasa P, Di Ciaula A, Garruti G, Vacca M, De Angelis M, Wang DQ. Bile acids and GPBAR-1: dynamic interaction involving genes, environment and gut microbiome. Nutrients. 2020;12:3709.
Valdovinos MA, Camilleri M, Zimmerman BR. Chronic diarrhea in diabetes mellitus: mechanisms and an approach to diagnosis and treatment. Mayo Clin Proc. 1993;68:691-702.
Ford AC, Sperber AD, Corsetti M, Camilleri M. Irritable bowel syndrome. Lancet. 2020;396:1675-1688.
Bonfrate L, Tack J, Grattagliano I, Cuomo R, Portincasa P. Microbiota in health and irritable bowel syndrome: current knowledge, perspectives and therapeutic options. Scand J Gastroenterol. 2013;48:995-1009.
Bonfrate L, Di Palo DM, Celano G, et al. Effects of Bifidobacterium longum BB536 and Lactobacillus rhamnosus HN001 in IBS patients. Eur J Clin Invest. 2020;n/a:e13201.
Wald A, Tunuguntla AK. Anorectal sensorimotor dysfunction in fecal incontinence and diabetes mellitus. Modification with biofeedback therapy. N Engl J Med. 1984;310:1282-1287.
Mourad FH, Gorard D, Thillainayagam AV, Colin-Jones D, Farthing MJ. Effective treatment of diabetic diarrhoea with somatostatin analogue, octreotide. Gut. 1992;33:1578-1580.
Schiller LR, Santa Ana CA, Morawski SG, Fordtran JS. Studies of the antidiarrheal action of clonidine. Effects on motility and intestinal absorption. Gastroenterology. 1985;89:982-988.
Rokkas T, Portincasa P. Colon neoplasia in patients with type 2 diabetes on metformin: a meta-analysis. Eur J Intern Med. 2016;33:60-66.
Portincasa P, Wang DQH. Gallstones. In: Podolsky KD, Camilleri M, Fitz JG, Kalloo AN, Shanahan F, Wang TC, eds. Yamada's Textbook of Gastroenterology. Wiley-Blackwell; 2015:1808-1834.
Wang HH, Li T, Portincasa P, et al. New insights into the role of Lith genes in the formation of cholesterol-supersaturated bile. Liver Res. 2017;1:42-53.
Wang DQH, Portincasa P. Gallstones. Recent Advances in Epidemiology, Pathogenesis, Diagnosis and Management. The First Edition. Nova Science Publisher Inc.; 2017:1-676.
Wang DQH, Neuschwander-Tetri BA, Portincasa P. The Biliary System, Second Edition. Vol. 8. Morgan & Claypool Life Sciences; 2017:i-178.
Wang DQ, Portincasa P, Tso P. Transintestinal cholesterol excretion: a secondary, nonbiliary pathway contributing to reverse cholesterol transport. Hepatology. 2017;66:1337-1340.
Portincasa P, Moschetta A, Palasciano G. Cholesterol gallstone disease. Lancet. 2006;368:230-239.
Portincasa P, Wang DQH. Gallstones. In: Podolsky KD, Camilleri M, Fitz JG, Kalloo AN, Shanahan F, Wang TC, eds. Yamada's Atlas of Gastroenterology. Wiley-Blackwell; 2016:335-353.
Di Ciaula A, Wang DQ, Portincasa P. Cholesterol cholelithiasis: part of a systemic metabolic disease, prone to primary prevention. Expert Rev Gastroenterol Hepatol. 2019;13:157-171.
Di Ciaula A, Wang DQ, Portincasa P. An update on the pathogenesis of cholesterol gallstone disease. Curr Opin Gastroenterol. 2018;34:71-80.
Di Ciaula A, Portincasa P. Recent advances in understanding and managing cholesterol gallstones. F1000Res. 2018;7:1529.
Wang DQH, Portincasa P, Wang HH. Bile formation and pathophysiology of gallstones. In: Kujpers EJ, ed. Encyclopedia of Gastroenterology. Academic Press: Elsevier; 2020:287-306.
Wang HH, Liu M, Portincasa P, Wang DQH. Lipid Transfer in Lipoprotein Metabolism and Cardiovascular Disease. Advances in Experimental Medicine and Biology. In: Jiang X-C, ed. Recent advances in the critical role of the sterol efflux transporters ABCG5/G8 in health and disease. Springer Singapore; 2020:105-136.
Wang F, Li G, Gu HM, Zhang DW. Characterization of the role of a highly conserved sequence in ATP binding cassette transporter G (ABCG) family in ABCG1 stability, oligomerization, and trafficking. Biochemistry. 2013;52:9497-9509.
Di Ciaula A, Garruti G, Wang DQH, Portincasa P. Diabetes and gallstones. In: Wang DQH, Portincasa P, eds. Gallstones. Recent Advances in Epidemiology, Pathogenesis, Diagnosis and Management. Nova Science Publisher Inc.; 2017:373-387.
Aune D, Vatten LJ. Diabetes mellitus and the risk of gallbladder disease: a systematic review and meta-analysis of prospective studies. J Diabetes Complications. 2016;30:368-373.
Chapman BA, Wilson IR, Frampton CM, et al. Prevalence of gallbladder disease in diabetes mellitus. Dig Dis Sci. 1996;41:2222-2228.
De Santis A, Attili AF, Ginanni Corradini S, et al. Gallstones and diabetes: a case-control study in a free-living population sample. Hepatology. 1997;25:787-790.
Palasciano G, Portincasa P, Belfiore A, et al. Gallbladder volume and emptying in diabetics: the role of neuropathy and obesity. J Intern Med. 1992;231:123-127.
Hahm JS, Park JY, Park KG, Ahn YH, Lee MH, Park KN. Gallbladder motility in diabetes mellitus using real time ultrasonography. Am J Gastroenterol. 1996;91:2391-2394.
Smelt AH. Triglycerides and gallstone formation. Clin Chim Acta. 2010;411:1625-1631.
Biddinger SB, Haas JT, Yu BB, et al. Hepatic insulin resistance directly promotes formation of cholesterol gallstones. Nat Med. 2008;14:778-782.
Ruhl CE, Everhart JE. Association of diabetes, serum insulin, and C-peptide with gallbladder disease. Hepatology. 2000;31:299-303.
Mendez-Sanchez N, Chavez-Tapia NC, Zamora-Valdes D, Medina-Santillan R, Uribe M. Hepatobiliary diseases and insulin resistance. Curr Med Chem. 2007;14:1988-1999.
Nakeeb A, Comuzzie AG, Al-Azzawi H, Sonnenberg GE, Kissebah AH, Pitt HA. Insulin resistance causes human gallbladder dysmotility. J Gastrointest Surg. 2006;10:940-948. discussion 8-9.
Tran KQ, Goldblatt MI, Swartz-Basile DA, Svatek C, Nakeeb A, Pitt HA. Diabetes and hyperlipidemia correlate with gallbladder contractility in leptin-related murine obesity. J Gastrointest Surg. 2003;7:857-862. discussion 63.
Attili AF, Capocaccia R, Carulli N, et al. Factors associated with gallstone disease in the MICOL experience. Multicenter Italian Study on Epidemiology of Cholelithiasis. Hepatology. 1997;26:809-818.
Wang TY, Portincasa P, Liu M, Tso P, Wang DQ. Mouse models of gallstone disease. Curr Opin Gastroenterol. 2018;34:59-70.
Fang S, Suh JM, Reilly SM, et al. Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance. Nat Med. 2015;21:159-165.
Fraquelli M, Pagliarulo M, Colucci A, Paggi S, Conte D. Gallbladder motility in obesity, diabetes mellitus and coeliac disease. Dig Liver Dis. 2003;35(Suppl 3):S12-S16.
Lee S, Kweon OK, Kim WH. Associations between serum leptin levels, hyperlipidemia, and cholelithiasis in dogs. PLoS One. 2017;12:e0187315.
Sun H, Tang H, Jiang S, et al. Gender and metabolic differences of gallstone diseases. World J Gastroenterol. 2009;15:1886-1891.
Tsai CJ, Leitzmann MF, Willett WC, Giovannucci EL. Long-term intake of dietary fiber and decreased risk of cholecystectomy in women. Am J Gastroenterol. 2004;99:1364-1370.
Tsai CJ, Leitzmann MF, Hu FB, Willett WC, Giovannucci EL. A prospective cohort study of nut consumption and the risk of gallstone disease in men. Am J Epidemiol. 2004;160:961-968.
Tsai CJ, Leitzmann MF, Willett WC, Giovannucci EL. Dietary carbohydrates and glycaemic load and the incidence of symptomatic gall stone disease in men. Gut. 2005;54:823-828.
Tsai CJ, Leitzmann MF, Willett WC, Giovannucci EL. Central adiposity, regional fat distribution, and the risk of cholecystectomy in women. Gut. 2006;55:708-714.
Tsunoda K, Shirai Y, Hatakeyama K. Prevalence of cholesterol gallstones positively correlates with per capita daily calorie intake. Hepatogastroenterology. 2004;51:1271-1274.
Misciagna G, Centonze S, Leoci C, et al. Diet, physical activity, and gallstones-a population-based, case- control study in southern Italy. Am J Clin Nutr. 1999;69:120-126.
Scragg RK, McMichael AJ, Baghurst PA. Diet, alcohol, and relative weight in gall stone disease: a case-control study. Br Med J (Clin Res Ed). 1984;288:1113-1119.
Attili AF, Scafato E, Marchioli R, Marfisi RM, Festi D. Diet and gallstones in Italy: the cross-sectional MICOL results. Hepatology. 1998;27:1492-1498.
Maclure KM, Hayes KC, Colditz GA, Stampfer MJ, Speizer FE, Willett WC. Weight, diet, and the risk of symptomatic gallstones in middle-aged women. N Engl J Med. 1989;321:563-569.
Sichieri R, Everhart JE, Roth H. A prospective study of hospitalization with gallstone disease among women: role of dietary factors, fasting period, and dieting. Am J Public Health. 1991;81:880-884.
Heaton KW, Emmett PM, Symes CL, Braddon FEM. An explanation for gallstones in normal-weight woman: slow intestinal transit. Lancet. 1993;341:8-10.
Stokes CS, Krawczyk M, Lammert F. Gallstones: environment, lifestyle and genes. Dig Dis. 2011;29:191-201.
Schwesinger WH, Kurtin WE, Page CP, Stewart RM, Johnson R. Soluble dietary fiber protects against cholesterol gallstone formation. Am J Surg. 1999;177:307-310.
Tsai CJ, Leitzmann MF, Willett WC, Giovannucci EL. Long-term intake of trans-fatty acids and risk of gallstone disease in men. Arch Intern Med. 2005;165:1011-1015.
Tsai CJ, Leitzmann MF, Willett WC, Giovannucci EL. Long-chain saturated fatty acids consumption and risk of gallstone disease among men. Ann Surg. 2008;247:95-103.
Abete I, Astrup A, Martinez JA, Thorsdottir I, Zulet MA. Obesity and the metabolic syndrome: role of different dietary macronutrient distribution patterns and specific nutritional components on weight loss and maintenance. Nutr Rev. 2010;68:214-231.
Tan J, Kou J. Advances in Research on the Pathogenesis of Type 2 Diabetes Complicated with Gallstone. Int J Clin Med. 2019;10:161.
Pasternak A, Bugajska J, Szura M, et al. Biliary polyunsaturated fatty acids and telocytes in gallstone disease. Cell Transplant. 2017;26:125-133.
Matyja A, Gil K, Pasternak A, et al. Telocytes: new insight into the pathogenesis of gallstone disease. J Cell Mol Med. 2013;17:734-742.
Faussone-Pellegrini MS, Grover M, Pasricha PJ, et al. Ultrastructural differences between diabetic and idiopathic gastroparesis. J Cell Mol Med. 2012;16:1573-1581.
Zhang Z, Tian J, Liao Q, Wang Y. The analysis of expression of CCK and IP3 receptors in gallstones patients with type 2 diabetes mellitus. Hepatogastroenterology. 2014;61:2173-2176.
Ding X, Lu CY, Mei Y, Liu CA, Shi YJ. Correlation between gene expression of CCK-A receptor and emptying dysfunction of the gallbladder in patients with gallstones and diabetes mellitus. Hepatobiliary Pancreat Dis Int. 2005;4:295-298.
Ponz de Leon M, Ferenderes R, Carulli N. Bile lipid composition and bile acid pool size in diabetes. Am J Dig Dis. 1978;23:710-716.
Ness GC, Edelman JL, Brooks PA. Involvement of tristetraprolin in transcriptional activation of hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase by insulin. Biochem Biophys Res Commun. 2012;420:178-182.
Mendez-Sanchez N, Bugianesi E, Gish RG, et al. Global multi-stakeholder endorsement of the MAFLD definition. Lancet Gastroenterol Hepatol. 2022;7:388-390.
de Vries M, Westerink J, El-Morabit F, Kaasjager H, de Valk HW. Prevalence of non-alcoholic fatty liver disease (NAFLD) and its association with surrogate markers of insulin resistance in patients with type 1 diabetes. Diabetes Res Clin Pract. 2022;186:109827.
Serdarova M, Dimova R, Chakarova N, et al. Metabolic determinants of NAFLD in adults with type 1 diabetes. Diabetes Res Clin Pract. 2022;186:109819.
Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011;34:274-285.
Williams CD, Stengel J, Asike MI, et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology. 2011;140:124-131.
Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73-84.
Younossi ZM, Golabi P, de Avila L, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis. J Hepatol. 2019;71:793-801.
Di Ciaula A, Bonfrate L, Krawczyk M, Frühbeck G, Portincasa P. Synergistic and detrimental effects of alcohol intake on progression of liver steatosis. Int J Mol Sci. 2022;23:2636.
Di Ciaula A, Calamita G, Shanmugam H, et al. Mitochondria matter: systemic aspects of nonalcoholic fatty liver disease (NAFLD) and diagnostic assessment of liver function by stable isotope dynamic breath tests. Int J Mol Sci. 2021;22:7702.
Portincasa P, Bonfrate L, Khalil M, et al. Intestinal barrier and permeability in health, obesity and NAFLD. Biomedicines. 2021;10:83.
Di Ciaula A, Baj J, Garruti G, et al. Liver steatosis, gut-liver axis, microbiome and environmental factors. a never-ending bidirectional cross-talk. J Clin Med. 2020;9:2648.
Di Ciaula A, Bonfrate L, Portincasa P. The role of microbiota in nonalcoholic fatty liver disease. Eur J Clin Invest. 2022;52:e13768.
Donga E, Dekkers OM, Corssmit EP, Romijn JA. Insulin resistance in patients with type 1 diabetes assessed by glucose clamp studies: systematic review and meta-analysis. Eur J Endocrinol. 2015;173:101-109.
de Vries M, Westerink J, Kaasjager K, de Valk HW. Prevalence of nonalcoholic fatty liver disease (NAFLD) in patients with type 1 diabetes mellitus: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2020;105:3842-3853.
de Vries M, El-Morabit F, van Erpecum KJ, et al. Non-alcoholic fatty liver disease: identical etiologic factors in patients with type 1 and type 2 diabetes. Eur J Intern Med. 2022;100:77-82.
Meyer G, Dauth N, Grimm M, Herrmann E, Bojunga J, Friedrich-Rust M. Shear wave elastography reveals a high prevalence of NAFLD-related fibrosis even in type 1 diabetes. Exp Clin Endocrinol Diabetes. 2021. doi:10.1055/a-1666-0431
Younossi ZM, Stepanova M, Afendy M, et al. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol. 2011;9:524-530. e1; quiz e60.
Palmentieri B, de Sio I, La Mura V, et al. The role of bright liver echo pattern on ultrasound B-mode examination in the diagnosis of liver steatosis. Dig Liver Dis. 2006;38:485-489.
Singh S, Allen AM, Wang Z, Prokop LJ, Murad MH, Loomba R. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol. 2015;13:643-654. e1-9; quiz e39-40.
Leeds JS, Hadjivassiliou M, Tesfaye S, Sanders DS. Lower gastrointestinal symptoms are associated with worse glycemic control and quality of life in type 1 diabetes mellitus. BMJ Open Diabetes Res Care. 2018;6:e000514.
Guo J, Liu C, Pan J, Yang J. Relationship between diabetes and risk of gastric cancer: a systematic review and meta-analysis of cohort studies. Diabetes Res Clin Pract. 2022;187:109866.
Harding JL, Shaw JE, Peeters A, Cartensen B, Magliano DJ. Cancer risk among people with type 1 and type 2 diabetes: disentangling true associations, detection bias, and reverse causation. Diabetes Care. 2015;38:264-270.
Sona MF, Myung SK, Park K, Jargalsaikhan G. Type 1 diabetes mellitus and risk of cancer: a meta-analysis of observational studies. Jpn J Clin Oncol. 2018;48:426-433.
De Melo EN, Clarke ABM, McDonald C, et al. Gastrointestinal symptoms in type 1 diabetes: relationship with autoimmune and microvascular complications. J Clin Endocrinol Metab. 2022;107:e2431-e2437.
Choung RS, Locke GR 3rd, Schleck CD, Zinsmeister AR, Melton LJ 3rd, Talley NJ. Risk of gastroparesis in subjects with type 1 and 2 diabetes in the general population. Am J Gastroenterol. 2012;107:82-88.
Wegeberg AL, Brock C, Ejskjaer N, et al. Gastrointestinal symptoms and cardiac vagal tone in type 1 diabetes correlates with gut transit times and motility index. Neurogastroenterol Motil. 2021;33:e13885.
Wegeberg AM, Liao D, Jensen SL, et al. Gastrocolic reflex is delayed and diminished in adults with type 1 diabetes. Dig Dis Sci. 2022. doi:10.1007/s10620-021-07346-y
Sarosiek I, Van Natta M, Parkman HP, et al. Effect of domperidone therapy on gastroparesis symptoms: results of a dynamic cohort study by NIDDK gastroparesis Consortium. Clin Gastroenterol Hepatol. 2022;20:e452-e464.
Sugumar A, Singh A, Pasricha PJ. A systematic review of the efficacy of domperidone for the treatment of diabetic gastroparesis. Clin Gastroenterol Hepatol. 2008;6:726-733.
Metoclopramide nasal spray (gimoti) for diabetic gastroparesis. JAMA. 2021;326:270-271.
Shakhatreh M, Jehangir A, Malik Z, Parkman HP. Metoclopramide for the treatment of diabetic gastroparesis. Expert Rev Gastroenterol Hepatol. 2019;13:711-721.
Camilleri M, Lembo A, McCallum R, et al. Overall safety of relamorelin in adults with diabetic gastroparesis: analysis of phase 2a and 2b trial data. Aliment Pharmacol Ther. 2020;51:1139-1148.
Camilleri M, McCallum RW, Tack J, Spence SC, Gottesdiener K, Fiedorek FT. Efficacy and safety of relamorelin in diabetics with symptoms of gastroparesis: a randomized, placebo-controlled study. Gastroenterology. 2017;153:1240-1250. e2.
Janssen P, Vos R, Van Oudenhove L, Tack J. Influence of the 5-HT3 receptor antagonist ondansetron on gastric sensorimotor function and nutrient tolerance in healthy volunteers. Neurogastroenterol Motil. 2011;23:444, e175-449.
Midani D, Parkman HP. Granisetron transdermal system for treatment of symptoms of gastroparesis: a prescription registry study. J Neurogastroenterol Motil. 2016;22:650-655.
Jacob D, Busciglio I, Burton D, et al. Effects of NK1 receptors on gastric motor functions and satiation in healthy humans: results from a controlled trial with the NK1 antagonist aprepitant. Am J Physiol Gastrointest Liver Physiol. 2017;313:G505-G510.
Carlin JL, Lieberman VR, Dahal A, et al. Efficacy and safety of tradipitant in patients with diabetic and idiopathic gastroparesis in a randomized, placebo-controlled trial. Gastroenterology. 2021;160:76, e4-87.
Andrews CN, Woo M, Buresi M, et al. Prucalopride in diabetic and connective tissue disease-related gastroparesis: randomized placebo-controlled crossover pilot trial. Neurogastroenterol Motil. 2021;33:e13958.
Noureddin S, Mohsen J, Payman A. Effects of psyllium vs. placebo on constipation, weight, glycemia, and lipids: a randomized trial in patients with type 2 diabetes and chronic constipation. Complement Ther Med. 2018;40:1-7.
Soltanian N, Janghorbani M. Effect of flaxseed or psyllium vs. placebo on management of constipation, weight, glycemia, and lipids: a randomized trial in constipated patients with type 2 diabetes. Clin Nutr ESPEN. 2019;29:41-48.
Prasad VGM, Abraham P. Management of chronic constipation in patients with diabetes mellitus. Indian J Gastroenterol. 2017;36:11-22.
Pieber TR, Svehlikova E, Mursic I, et al. Blood glucose response after oral lactulose intake in type 2 diabetic individuals. World J Diabetes. 2021;12:893-907.
Christie J, Shroff S, Shahnavaz N, et al. A randomized, double-blind, placebo-controlled trial to examine the effectiveness of lubiprostone on constipation symptoms and colon transit time in diabetic patients. Am J Gastroenterol. 2017;112:356-364.
Piper MS, Saad RJ. Diabetes Mellitus and the Colon. Curr Treat Options Gastroenterol. 2017;15:460-474.
Camilleri M, Malhi H, Acosta A. Gastrointestinal complications of obesity. Gastroenterology. 2017;152:1656-1670.
Phatak UP, Pashankar DS. Obesity and gastrointestinal disorders in children. J Pediatr Gastroenterol Nutr. 2015;60:441-445.
Schnermann ME, Schulz CA, Perrar I, et al. A healthy lifestyle during adolescence was inversely associated with fatty liver indices in early adulthood - findings from the DONALD cohort study. Br J Nutr. 2022:1-23. doi:10.1017/S0007114522001313
Ness-Jensen E, Hveem K, El-Serag H, Lagergren J. Lifestyle intervention in gastroesophageal reflux disease. Clin Gastroenterol Hepatol. 2016;14:175-182. e1-3.
Davis J, Camilleri M, Eckert D, Burton D, Joyner M, Acosta A. Physical activity is associated with accelerated gastric emptying and increased ghrelin in obesity. Neurogastroenterol Motil. 2020;32:e13879.
Sarsangi P, Salehi-Abargouei A, Ebrahimpour-Koujan S, Esmaillzadeh A. Association between adherence to the mediterranean diet and risk of Type 2 diabetes: an updated systematic review and dose-response meta-analysis of prospective cohort studies. Adv Nutr. 2022. doi:10.1093/advances/nmac046
Vitale M, Masulli M, Calabrese I, et al. Impact of a mediterranean dietary pattern and its components on cardiovascular risk factors, glucose control, and body weight in people with type 2 diabetes: a real-life study. Nutrients. 2018;10:1067.
Schlesinger S, Neuenschwander M, Ballon A, Nothlings U, Barbaresko J. Adherence to healthy lifestyles and incidence of diabetes and mortality among individuals with diabetes: a systematic review and meta-analysis of prospective studies. J Epidemiol Community Health. 2020;74:481-487.
Masuda H, Ishiyama D, Yamada M, et al. Relationship between long-term objectively measured physical activity and glycemic control in type 2 diabetes mellitus patients: a prospective cohort study. Diabetes Metab Syndr Obes. 2021;14:2057-2063.
Yang M, Cheng H, Shen C, et al. Effects of long-term exposure to air pollution on the incidence of type 2 diabetes mellitus: a meta-analysis of cohort studies. Environ Sci Pollut Res Int. 2020;27:798-811.
Sorensen M, Poulsen AH, Hvidtfeldt UA, et al. Exposure to source-specific air pollution and risk for type 2 diabetes: a nationwide study covering Denmark. Int J Epidemiol. 2022. doi:10.1093/ije/dyac040
Khafaie MA, Salvi SS, Ojha A, Khafaie B, Gore SD, Yajnik CS. Particulate matter and markers of glycemic control and insulin resistance in type 2 diabetic patients: result from Wellcome Trust Genetic study. J Expo Sci Environ Epidemiol. 2018;28:328-336.
Di Ciaula A, Portincasa P. Relationships between emissions of toxic airborne molecules and type 1 diabetes incidence in children: an ecologic study. World J Diabetes. 2021;12:673-684.
Di Ciaula A. Type I diabetes in paediatric age in Apulia (Italy): Incidence and associations with outdoor air pollutants. Diabetes Res Clin Pract. 2016;111:36-43.
Song Y, Chou EL, Baecker A, et al. Endocrine-disrupting chemicals, risk of type 2 diabetes, and diabetes-related metabolic traits: a systematic review and meta-analysis. J Diabetes. 2016;8:516-532.
Schulz MC, Sargis RM. Inappropriately sweet: environmental endocrine-disrupting chemicals and the diabetes pandemic. Adv Pharmacol. 2021;92:419-456.
Swinburn BA, Kraak VI, Allender S, et al. The global syndemic of obesity, undernutrition, and climate change: the Lancet commission report. Lancet. 2019;393:791-846.
Di Ciaula A, Portincasa P. Diet and contaminants: driving the rise to obesity epidemics? Curr Med Chem. 2019;26:3471-3482.
Portincasa P, Bonfrate L, Vacca M, et al. Gut microbiota and short chain fatty acids: implications in glucose homeostasis. Int J Mol Sci. 2022;23:1105.
Jones RM, Neish AS. Gut microbiota in intestinal and liver disease. Annu Rev Pathol. 2021;16:251-275.
Megur A, Daliri EB, Baltriukiene D, Burokas A. Prebiotics as a tool for the prevention and treatment of obesity and diabetes: classification and ability to modulate the gut microbiota. Int J Mol Sci. 2022;23:6097.
Suh S, Kim KW. Diabetes and cancer: cancer should be screened in routine diabetes assessment. Diabetes Metab J. 2019;43:733-743.